FDA Proposes Priorities For Cosmetic Ingredient Review: Mica, Probiotics, CBD
Executive Summary
Nakissa Sadrieh, director of cosmetics at FDA and the agency’s CIR liaison, floated the three potential review priorities at the CIR Expert Panel’s April 8-9 meeting in Washington. It’s the most for-cause targets proposed by the agency in recent memory, and CIR leadership noted that they pose considerable challenges.
You may also be interested in...
CIR Expert Panel To Prioritize Cannabidiol Review In 2024 At FDA’s Request
Cosmetic Ingredient Review’s independent experts note that CBD use in cosmetic products has increased since FDA first asked them to prioritize its review in 2020.
Dutch Biotech Touts Enzyme-Powered Eczema Cream As ‘Smarter And Safer’ Solution
Headquartered in The Hague, Netherlands, Micreos is focused on developing targeted antibacterial products to replace antibiotics, protect against food contamination and treat inflammatory skin conditions. The firm’s Gladskin Eczema Cream, now available stateside, uses a patented enzyme technology to destroy Staphylococcus aureus bacteria while leaving skin’s beneficial flora intact.
Bayer Harnessing Skin Microbiome In New Product Development
Bayer has teamed up with skin microbiome specialist Azitra to develop consumer health products for a host of conditions.